Trials / Completed
CompletedNCT02150343
Phase II HDM-SPIRE Safety and Efficacy Study
A Double-Blind, Randomised, Placebo-Controlled, Multi-Centre Field Study to Assess the Efficacy and Safety of HDM-SPIRE in Subjects With a History of House Dust Mite-Induced Rhinoconjunctivitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 715 (actual)
- Sponsor
- Circassia Limited · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the treatment effect of three treatment regimens of HDM-SPIRE vs placebo and to evaluates the treatment effect of HDM-SPIRE on symptoms, rescue medication usage, Quality of Life and Sleep Quality
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HDM-SPIRE | 1 dose every 4 weeks |
| DRUG | Placebo | 1 dose every 4 weeks |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2017-04-13
- Completion
- 2017-04-13
- First posted
- 2014-05-29
- Last updated
- 2018-06-15
- Results posted
- 2018-06-15
Locations
98 sites across 8 countries: United States, Canada, France, Germany, Italy, Netherlands, South Africa, Spain
Source: ClinicalTrials.gov record NCT02150343. Inclusion in this directory is not an endorsement.